Wells Fargo & Company Arcturus Therapeutics Holdings Inc. Transaction History
Wells Fargo & Company
- $468 Billion
- Q2 2025
A detailed history of Wells Fargo & Company transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 22,446 shares of ARCT stock, worth $491,118. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,446
Previous 18,628
20.5%
Holding current value
$491,118
Previous $197,000
48.22%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ARCT
# of Institutions
171Shares Held
25.9MCall Options Held
321KPut Options Held
136K-
Federated Hermes, Inc. Pittsburgh, PA4.69MShares$103 Million0.12% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$58 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.1.83MShares$40.1 Million0.02% of portfolio
-
Nikko Asset Management Americas, Inc.1.83MShares$40 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.81MShares$39.6 Million0.0% of portfolio
About Arcturus Therapeutics Holdings Inc.
- Ticker ARCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,576,400
- Market Cap $581M
- Description
- Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...